A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If ...
GlobalData on MSN
Japan’s MHLW grants orphan status to Kyowa and Orchard’s MLD therapy
Japan's Ministry of Health, Labor and Welfare (MHLW) has granted orphan regenerative medicine product designation to Kyowa ...
News-Medical.Net on MSN
New approach harnesses tumor's own machinery to produce immune-stimulating molecules
By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers ...
The FDA has officially placed two of Intellia’s Phase III studies under clinical hold after the biotech reported earlier this ...
The U.S. Food and Drug Administration has placed a clinical hold on Intellia Therapeutics' two late-stage trials testing an ...
ArcticZymes Technologies ASA ( ($DE:B4V) ) has shared an update. ArcticZymes Technologies ASA has entered into an exclusive distribution agreement ...
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers have found a way to force tumors to trigger their own destruction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback